Longitudinal Outcomes in Youth with Type 2 Diabetes—The TODAY2 Study
Kimberly L. Drews, MD, PhD
George Washington University, DC, USA Lorraine E. Levy Katz, MD
Children’s Hospital of Philadelphia, PA, USA Petter Bjornstad, MD
University of Colorado, CO, USA Neil H. White, MD
Washington University in St. Louis, LA, USA Jeanie B. Tryggestad, MD
University of Oklahoma, OK, USA Ruth S. Weinstock, MD, PhD
SUNY Upstate Medical University, NY, USA for the TODAY2 Study Group
The TODAY study found that type 2 diabetes in youth is a more aggressive disorder than in adults, with higher medication failure, more rapid b-cell decline, and accelerated appearance of complications.
TODAY2 is a post-intervention follow-up study of TODAY with the primary objective of monitoring progression of type 2 diabetes and complications as individuals transition to young adulthood.
The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) Study was the first multiethnic, multicenter, randomized trial examining youth-onset type 2 diabetes (Y-T2D). TODAY2 is a follow-up study that tracked the progression of type 2 diabetes and related comorbidities and complications as the participants transition to young adulthood. Data from this cohort allows better understanding on the development of renal, cardiac, eye, and nervous system complications, as well as data on pregnancy outcomes and health care utilization in this vulnerable population.
Eligible patients in the TODAY trial were 10 to 17 years of age and treated with metformin (at a dose of 1,000 mg twice daily) to attain a HbA1c level <8% and were randomly assigned to continued treatment with metformin alone or to metformin combined with rosiglitazone (4 mg twice a day) or a lifestyle intervention program focusing on weight loss through eating and activity behaviors.
Total number of enrollees: 517 patients in phase 2 of the follow-up.
Mean age 21.2 years, mean HbA1c of 9.3%, and mean BMI of 36.3 kg/m2.
Mean of 6.9 years since diagnosis.
Cardiac, renal, eye, and nervous system complications were recorded, as well as data on pregnancy outcomes and health care utilization.
Present disclosure: K.L. Drews, L.E. Levy Katz, P. Bjornstad, and J.B. Tryggestad: the presenters has reported that no relationships exist relevant to the contents of this presentation. N.H. White: Daiichi-Sankyo. R.S. Weinstock: Medtronic, Minimed, Diasome Pharmaceuticals, Oramed Ltd, Kowa research Inst., Boehringer Ingelheim, Eli Lilly, Insulogic LLC.
Jose C. Florez, MD, PhD
Chair, ADA Scientific Sessions Meeting Planning Committee
The 79th American Diabetes Association’s Scientific Sessions were held in San Francisco, California from June 7-11, 2019. The meeting was attended by over 15,000 professional attendees from 115 countries, … [ Read all ]
Presented by: Alison B. Evert, MD; Janice MacLeod, MA, RDN, CDE; William S. Yancy, Jr., MD, MHS; W. Timothy Garvey, MD; Ka Hei Karen Lau, MS, RD, LDN, CDE; Christopher D. Gardner, PhD; Kelly M. Rawlings, MS